Related Experiment Video
Updated: May 5, 2026

A Method for Islet Transplantation to the Omentum in Mouse
Published on: January 7, 2019
Diabetes Mellitus and Osteoporosis After Organ Transplantation: Frequency, Clinical Features, and Treatment
Theresia Sarabhai1, Annie Mathew1, Jassin Rashidi-Alavijeh2
1Department of Endocrinology, Diabetology and Metabolism, University Hospital Essen, University Duisburg-Essen, Essen, Germany
Background:
Organ transplantation is an effective treatment option, often the last remaining one, for terminal organ failure. 22-32% of transplant recipients, however, develop metabolic-endocrine complications that markedly impair transplant function and overall survival. We provide an evidence-based narrative review of the clinical features, diagnostic evaluation, and treatment of post-transplantation diabetes mellitus (PTDM) and osteoporosis.
Methods:
This review is based on pertinent publications that were retrieved by a selective search in PubMed, MEDLINE, and the Cochrane Library (01/1995-09/2025), including systematic reviews, clinical studies, randomized controlled trials, register data analyses, observational studies, and guidelines.
Results:
Post-transplantation diabetes affects 9-40% of organ recipients in the first year after transplantation, corresponding to a two- to threefold risk elevation compared to the general population. Its incidence and course are organ-specific and characterized by further risk factors, including a 3.3-fold elevation of the risk of cardiovascular events. Studies have shown that, alongside insulin and metformin, newer antidiabetic agents such as GLP-1 receptor agonists and SGLT2 inhibitors also improve glycemic control, reduce cardiovascular events, and, as far as can be determined, do not endanger the transplant. Transplantation-associated osteoporosis affects 23-67% of transplant recipients, causing the most marked bone loss in the first 6-18 months after transplantation. Approximately 20% of the affected patients sustain fractures. Bisphosphonate, denosumab, and teriparatide have been found to be treatment options. Treatment should be initiated as early as possible.
Conclusion:
Thorough screening and timely, specialist-coordinated interdisciplinary care in specialized transplantation centers are decisive for the recognition and risk-adapted, evidence-based treatment of PTDM and transplantation-associated osteoporosis.
More Related Videos
02:08Surgical Bone Implantation Technique for Rat Tibia Models of Diabetes and Osteoporosis
Published on: July 5, 2024
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
Related Concept Videos
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Kidney Transplant III: Nursing Management
Type I Diabetes III: Clinical Manifestations
Complications of Diabetes Mellitus
Diabetic Nephropathy